SAN FRANCISCO, April 03, 2017 — King & Spalding advised Delaware-based biopharmaceutical company Incyte Corp. on two recently announced master clinical trial drug collaboration agreements, with Merck and with BMS.
Under the new master clinical trial collaboration and supply agreement with Merck, the parties will expand their existing collaboration (on which King & Spalding also advised, in 2015), which involved combining Merck’s approved antibody Keytruda® with Incyte’s investigational drug epacadostat, a selective IDO1 inhibitor, in a Phase 3 trial as first-line therapy for treatment of melanoma. Under the new master agreement, the parties will investigate the same drug combination in additional Phase 3 clinical trials for the treatment of a number of different cancers, including non-small cell lung cancer, head and neck cancer, bladder cancer and renal cancer. This expansion of the companies’ collaboration was originally announced in January; this week, the companies announced they had formally signed the master agreement to implement the expansion.
King & Spalding also advised Incyte on its expanded clinical trial collaboration with BMS, under which the parties will initiate Phase 3 clinical trials combining Incyte’s epacadostat with BMS’s approved antibody Opdivo® for treatment of head and neck cancer and non-small cell lung cancer.
The King & Spalding team on these deals included partner Tom Duley and senior associate Stephen Abreu, who are both based in San Francisco. King & Spalding advises pharmaceutical, biotechnology, medical technology and other clients in the life sciences industry at all stages of their development and in connection with a wide variety of strategic corporate transactions. Law360 recently named King & Spalding’s team a Life Sciences Practice Group of the Year.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1000 lawyers in 19 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.